Biotech companies in the United States by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Biogen has the lowest figure of the 15 biotech companies in the United States ranked by P/S ratio, at 3.7, followed by Neurocrine Biosciences (5.4) and Amgen (6.5). Figures as of 20 Nov 2026, 18:22 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 15
- Lowest
- Biogen3.7
- Median
- 14.3
- Combined market value
- SEK 7.5T
- Countries
- 1
- Not ranked
- 5no P/S ratio on file
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 3.7 | SEK 377.6B | SEK 2,554.43 | 1.16% up | 41% up | ||
| 2 | Neurocrine BiosciencesNBIX · Health Care | 5.4 | SEK 158.6B | SEK 1,567.34 | 2.04% down | 10% up | ||
| 3 | AmgenAMGN · Health Care | 6.5 | SEK 2.43T | SEK 4,486.96 | 0.65% up | 30% up | ||
| 4 | ExelixisEXEL · Health Care | 6.9 | SEK 163.6B | SEK 670.49 | 0.32% down | 55% up | ||
| 5 | Gilead SciencesGILD · Health Care | 7.1 | SEK 2.14T | SEK 1,722.19 | 1.21% up | 31% up | ||
| 6 | Halozyme TherapeuticsHALO · Health Care | 7.6 | SEK 108.3B | SEK 949.84 | 0.09% down | 32% up | ||
| 7 | Bio-TechneTECH · Health Care | 9.4 | SEK 116.7B | SEK 743.03 | 0.03% up | 18% up | ||
| 8 | RepligenRGEN · Health Care | 14.3 | SEK 107.8B | SEK 1,687.15 | 3.04% down | 5% up | ||
| 9 | Adaptive BiotechnologiesADPT · Health Care | 16.3 | SEK 46.1B | SEK 284.56 | 0.71% down | 51% up | ||
| 10 | Twist BioscienceTWST · Health Care | 19.1 | SEK 73.5B | SEK 1,077.41 | 5.53% down | 291% up | ||
| 11 | Krystal BiotechKRYS · Health Care | 24.0 | SEK 95.4B | SEK 3,219.04 | 0.25% down | 49% up | ||
| 12 | ModernaMRNA · Health Care | 40.7 | SEK 808.1B | SEK 1,997.20 | 1.94% down | 740% up | ||
| 13 | ImmunityBioIBRX · Health Care | 57.0 | SEK 66B | SEK 62.02 | 7.61% down | 216% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | 251 | SEK 100.5B | SEK 1,177.69 | 3.46% down | 81% up | ||
| 15 | CG OncologyCGON · Health Care | 1789 | SEK 73.9B | SEK 826.82 | 1.20% down | 93% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 10.2177 SEK). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which biotech companies in the United States have the lowest P/S ratio?
Biogen (3.7), Neurocrine Biosciences (5.4) and Amgen (6.5) have the lowest P/S ratio of the 15 biotech companies in the United States ranked here as of 20 Nov 2026, 18:22 UTC.
How many biotech companies in the United States are in this ranking?
15 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these biotech companies in the United States worth together?
The 15 biotech companies in the United States ranked by P/S ratio have a combined market value of SEK 7.5T as of 20 Nov 2026, 18:22 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech companies in the United States by P/S ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.